Skip to content

Study · Observational study · 2020

2 results

935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial

Rahman F, de Chantal M, Mesquita P, Aberg J

Open forum infectious diseases1 Oct 2020

PMCIDPMC7776066 (opens in a new tab)PepBankPUB-96617186
Read at sourceSource pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In tesamorelin-treated people with HIV who were selected as responders (at least 8% VAT decrease), VAT decreased at week 26 both with and without dorsocervical fat; there was no placebo comparison.

    In plain wordsIn people with HIV who responded to tesamorelin (8% or more belly fat loss), belly fat fell by week 26, with or without neck fat.

    Peptide
    Tesamorelin
    Outcome
    DecreaseVisceral adipose tissue change at week 26 with and without dorsocervical fat
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a decrease in VAT and also an improvement in their WC at week 26 in both groups.
    2 context sentences
    Summary · context
    Participants were randomized to receive tesamorelin 2 mg daily or placebo daily for 26 weeks.
    Summary · context
    Only tesamorelin responders, defined as patients with at least 8% decrease in VAT and who were adherent to the medication, were used for this analysis.
  2. 02HumanObservational studyEfficacy outcome

    In tesamorelin-treated people with HIV who were selected as responders (at least 8% VAT decrease), waist circumference improved at week 26 both with and without dorsocervical fat; there was no placebo comparison.

    In plain wordsIn people with HIV who responded to tesamorelin (8% or more belly fat loss), waist size improved by week 26, with or without neck fat.

    Peptide
    Tesamorelin
    Outcome
    Direction not reportedWaist circumference change at week 26 with and without dorsocervical fat
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg daily · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a decrease in VAT and also an improvement in their WC at week 26 in both groups.
    2 context sentences
    Summary · context
    Participants were randomized to receive tesamorelin 2 mg daily or placebo daily for 26 weeks.
    Summary · context
    Only tesamorelin responders, defined as patients with at least 8% decrease in VAT and who were adherent to the medication, were used for this analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.